| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
2,5-Dibromothiazole inhibits bacterial growth by binding to the cell wall and preventing the synthesis of proteins required for cell division. This suggests that the compound may target bacterial cell wall synthesis or protein synthesis machinery. The compound is also used in the preparation of arylthiazolylpiperidine derivatives and analogs for use as survival motor neuron (SMN) protein production modulators. SMN protein is essential for the survival of motor neurons, and its deficiency causes spinal muscular atrophy. Modulators of SMN protein production are being investigated for the treatment of spinal muscular atrophy. The compound's thiazole ring and bromine substituents provide reactive sites for further functionalization, enabling the synthesis of derivatives with potential biological activity.
|
|---|---|
| ln Vitro |
In vitro, 2,5-dibromothiazole is a key intermediate in organic synthesis. It is used in the preparation of arylthiazolylpiperidine derivatives and analogs for use as SMN protein production modulators. The compound inhibits bacterial growth by binding to the cell wall and preventing the synthesis of proteins required for cell division. It is a high-purity biochemical reagent suitable for use as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery. In medicinal chemistry, it serves as a versatile building block for constructing biologically active molecules. Its dual bromine substitution allows for selective functionalization through cross-coupling reactions. In organic synthesis, it is used as a building block for creating complex molecules efficiently.
|
| ln Vivo |
In vivo activity is mediated through the derivatives of 2,5-dibromothiazole rather than the parent compound itself. For example, arylthiazolylpiperidine derivatives and analogs for use as SMN protein production modulators are evaluated in animal models of spinal muscular atrophy. The compound's antibacterial activity suggests potential for in vivo evaluation in animal models of bacterial infection, but specific studies on the parent compound are limited. The parent compound itself is not typically administered in vivo.
|
| Enzyme Assay |
Cell-free assays involving 2,5-dibromothiazole are focused on its use as a chemical reagent. Standard cross-coupling protocols involve mixing the compound with a coupling partner, a palladium catalyst, a base, and a solvent under inert atmosphere. The reaction progress is monitored by TLC or HPLC. For the preparation of arylthiazolylpiperidine derivatives, the compound is used as a starting material in multi-step synthetic routes. The compound's reactivity can be studied using various analytical techniques, including NMR spectroscopy and mass spectrometry. Its use as a solvent for organic reactions is also documented.
|
| Cell Assay |
Cellular assays are not commonly performed with 2,5-dibromothiazole itself, as it is a chemical intermediate rather than a bioactive compound. However, its derivatives, such as arylthiazolylpiperidine derivatives, may be evaluated in cell-based systems for SMN protein production modulation. The compound's antibacterial activity may be evaluated in bacterial cultures. The compound itself is not used as a test article in mammalian cell-based experiments due to its primary role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not typically conducted with the parent compound 2,5-dibromothiazole. Its derivatives, such as arylthiazolylpiperidine derivatives for SMN protein production modulation, are evaluated in animal models of spinal muscular atrophy. The compound's antibacterial activity suggests potential for in vivo evaluation in animal models of bacterial infection, but specific studies on the parent compound are limited. The parent compound is not administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,5-dibromothiazole are not available. As a small polar molecule with a molecular weight of 242.92 g/mol, it is expected to have moderate bioavailability if administered, but it is not intended for therapeutic use. Comprehensive pharmacokinetic studies have not been performed, as the compound is not intended for systemic administration. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,5-dibromothiazole are limited. Standard safety precautions for handling halogenated heterocycles apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
2,5-Dibromothiazole is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a key intermediate in organic synthesis and is used in the preparation of arylthiazolylpiperidine derivatives and analogs for use as SMN protein production modulators. The compound inhibits bacterial growth by binding to the cell wall and preventing the synthesis of proteins required for cell division. It can also be used as a solvent for organic reactions and may be used for the production of pharmaceuticals. It is a high-purity biochemical reagent suitable for use as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery. It should be stored in a cool, dry place.
|
| Molecular Formula |
C3HBR2NS
|
|---|---|
| Molecular Weight |
242.92
|
| Exact Mass |
240.819
|
| CAS # |
4175-78-4
|
| PubChem CID |
312394
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Boiling Point |
242.8±13.0 °C at 760 mmHg
|
| Melting Point |
45-49 °C(lit.)
|
| Flash Point |
100.6±19.8 °C
|
| Vapour Pressure |
0.1±0.5 mmHg at 25°C
|
| Index of Refraction |
1.650
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
70
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=CN=C(S1)Br
|
| InChi Key |
XIBIQFJKUZZLLX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3HBr2NS/c4-2-1-6-3(5)7-2/h1H
|
| Chemical Name |
2,5-dibromo-1,3-thiazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1166 mL | 20.5829 mL | 41.1658 mL | |
| 5 mM | 0.8233 mL | 4.1166 mL | 8.2332 mL | |
| 10 mM | 0.4117 mL | 2.0583 mL | 4.1166 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
